Filing Scope and Business Context
Important identity note: The submitted filing is Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), not Spyre Therapeutics, Inc. It is a Form 10-Q for the quarter and six months ended June 30, 2021, filed August 5, 2021. Aeglea was a clinical-stage biotechnology company developing engineered human enzyme therapeutics for rare metabolic diseases. The interim financial statements are unaudited.
- Lead candidate: pegzilarginase for Arginase 1 Deficiency, in the global Phase 3 PEACE trial.
- Other clinical candidate: AGLE-177 for Homocystinuria, with first-patient dosing in a Phase 1/2 trial initiated in June 2021.
- The Company had no approved products and no product sales revenue.
Financial Performance and Position
| Metric | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 |
|---|---|---|---|---|
| Total revenue | $13.7 million | $0 | $13.7 million | $0 |
| Research and development expense | $13.6 million | $16.9 million | $25.4 million | $31.4 million |
| General and administrative expense | $6.8 million | $4.7 million | $13.2 million | $9.2 million |
| Loss from operations | $(6.7) million | $(21.6) million | $(24.9) million | $(40.6) million |
| Net loss | $(6.8) million | $(21.4) million | $(25.0) million | $(40.1) million |
| Basic and diluted loss per share | $(0.10) | $(0.40) | $(0.38) | $(0.93) |
- Second-quarter operating margin was approximately (49%); net margin was approximately (50%). Six-month operating and net margins were approximately (182%) and (183%), respectively, because revenue was limited to license and development activity rather than product sales.
- Revenue consisted of $12.0 million of license revenue and $1.7 million of development revenue under the Immedica agreement.
- Cash, cash equivalents and marketable securities totaled $128.6 million at June 30, 2021; including $1.8 million of restricted cash, total liquidity was $130.4 million.
- Working capital was $113.8 million and accumulated deficit was $301.1 million.
- The Company reported no debt or credit facility. Lease liabilities were reported, including $7.5 million of future minimum commitments through April 2028.
- Net cash used in operating activities was $17.4 million for the first six months, versus $41.1 million in the prior-year period.
- Net cash used in investing activities was $38.1 million, primarily reflecting purchases of marketable securities. Financing activities provided $0.2 million, compared with $129.6 million in the prior-year period from a public offering.
- Cash, cash equivalents and restricted cash decreased by $55.3 million during the first six months, ending at $36.6 million; marketable securities increased substantially to $93.8 million.
Material Changes Versus the Prior Comparable Period
- Revenue increased from zero to $13.7 million because of the March 2021 Immedica license and development agreement.
- Quarterly and year-to-date net losses narrowed by $14.6 million and $15.1 million, respectively, primarily due to the new license and development revenue and lower manufacturing costs.
- Research and development expense decreased 20% in the quarter and 19% year to date, mainly because certain pre-commercial pegzilarginase manufacturing activities were completed. Clinical and nonclinical spending increased for the PEACE and AGLE-177 programs.
- General and administrative expense increased 45% in the quarter and 44% year to date, reflecting additional commercial-planning personnel, stock-based compensation, professional services and legal costs.
- The Immedica agreement generated a $21.5 million upfront payment. The Company recognized $13.7 million of related revenue and recorded $7.8 million of deferred revenue at June 30, 2021, including $5.5 million classified as current.
- Common shares outstanding increased to approximately 49.0 million at June 30, 2021 from approximately 48.0 million at December 31, 2020. In addition, 16.6 million pre-funded warrants remained outstanding.
Guidance, Outlook, Risks and Unusual Items
- Management believed existing cash, cash equivalents and marketable securities were sufficient to fund operations into 2023, but stated that additional financing will be required for all planned research, development and commercialization activities.
- Topline data from the Phase 3 PEACE trial was expected in the fourth quarter of 2021 after randomization of 32 patients, exceeding the 30-patient target.
- The AGLE-177 Phase 1/2 trial was expected to enroll 16 to 20 patients, with a clinical update anticipated before year-end 2021.
- The Immedica agreement provides potential regulatory and commercial milestones of up to approximately $130.0 million and royalties in the mid-20% range on net sales in the licensed territories. These amounts were excluded from current revenue because achievement or sales were uncertain.
- COVID-19 caused prior screening suspensions, missed dosing and enrollment or operational disruptions and could continue to affect clinical trials, manufacturing, supply chains, site monitoring, regulatory review and data quality.
- Key risks include clinical-trial failure or delay, regulatory non-approval, safety or immunogenicity issues, dependence on third-party manufacturers and CROs, intellectual-property disputes, limited product-market opportunities, reimbursement uncertainty and the need for additional capital.
- The Company had not achieved profitability and expected continued operating losses. Equity financing could dilute existing stockholders; the filing also disclosed an effective shelf registration and remaining availability under an at-the-market program.
- Management reported effective disclosure controls at June 30, 2021, with no material changes in internal control over financial reporting during the quarter. No material legal proceedings were reported.
Investor Verification Priorities
- Verify the company identity: the source filing is for Aeglea BioTherapeutics, Inc., not Spyre Therapeutics, Inc.
- Confirm the accounting and durability of the $13.7 million Immedica revenue, including the remaining $7.8 million deferred revenue and future performance obligations.
- Track Phase 3 PEACE trial topline results, regulatory interactions and the timing and content of any BLA submission.
- Assess cash burn, marketable-securities liquidity and the stated funding runway into 2023 against actual clinical, manufacturing and commercialization spending.
- Monitor potential dilution from future equity offerings and exercise of the 16.6 million outstanding pre-funded warrants.
- Evaluate COVID-19-related trial, manufacturing and supply-chain disruptions, as well as clinical safety, efficacy and enrollment risks for pegzilarginase and AGLE-177.